ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF

Abivax S.A.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026

$87.49−0.64 (-0.73%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Abivax has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Abivax filed with the SEC

Sep 21, 2026, 4:12 PM ET
Abivax Presents Business Updates and
EX-99.1 to Form 6-K
Jun 29, 2026, 5:22 PM ET
Abivax Reports Positive ABTECT Maintenance
EX-99.1 to Form 6-K
Jun 2, 2026, 6:01 AM ET
Abivax Announces Landmark Phase 3 ABTECT
EX-99.1 to Form 6-K
May 22, 2026, 4:12 PM ET
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose
EX-99.1 to Form 6-K
May 20, 2026, 4:47 PM ET
Abivax Annouces Results of its May 11, 2026 Annual General Meeting
EX-99.1 to Form 6-K
May 7, 2026, 4:03 PM ET
Royalty Certificates and Pricing of $45M
EX-99.1 to Form 6-K
Apr 20, 2026, 4:07 PM ET
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026
EX-99.1 to Form 6-K
Mar 23, 2026, 4:49 PM ET
Abivax Announces Full Year 2025 Financial Results and Provides
EX-99.1 to Form 6-K
Feb 23, 2026, 4:05 PM ET
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EX-99.1 to Form 6-K
Dec 15, 2025, 4:13 PM ET
Abivax Presents Third Quarter 2025 Financial Results
EX-99.1 to Form 6-K
Sep 8, 2025, 4:05 PM ET
Abivax Presents First Half 2025 Financial Results
EX-99.1 to Form 6-K
Jul 22, 2025, 5:17 PM ET
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week
EX-99.1 to Form 6-K
Jun 11, 2025, 4:01 PM ET
Abivax Announces Results of its June 6, 2025 Annual General Meeting
EX-99.1 to Form 6-K
Jun 2, 2025, 4:04 PM ET
Abivax Presents First Quarter 2025 Financial Results
EX-99.1 to Form 6-K
Apr 29, 2025, 4:04 PM ET
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
EX-99.1 to Form 6-K
Apr 22, 2025, 5:20 PM ET
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving
EX-99.1 to Form 6-K
Apr 22, 2025, 5:20 PM ET
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
EX-99.2 to Form 6-K
Mar 24, 2025, 6:04 AM ET
Abivax Announces Full Year 2024 Financial Results
EX-99.1 to Form 6-K
Jan 10, 2025, 9:04 AM ET
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
EX-99.1 to Form 6-K
Dec 23, 2024, 5:14 PM ET
Abivax Announces a Change to the Composition of its Board of Directors
EX-99.1 to Form 6-K
Nov 19, 2024, 4:43 PM ET
PARIS, France, November 19, 2024 10:30 p.m. CET Abivax SA (Euronext Paris: FR0012333284 ABVX / Nasdaq - ABVX)
EX-99.1 to Form 6-K
Nov 14, 2024, 4:00 PM ET
Abivax presents third quarter 2024 key financial information
EX-99.1 to Form 6-K
Oct 3, 2024, 4:18 PM ET
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s
EX-99.1 to Form 6-K
Oct 3, 2024, 6:05 AM ET
Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients
EX-99.1 to Form 6-K
Sep 26, 2024, 6:05 AM ET
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
EX-99.1 to Form 6-K
Sep 25, 2024, 4:30 PM ET
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
EX-99.1 to Form 6-K
Sep 9, 2024, 4:27 PM ET
Abivax presents first-half 2024 financial results
EX-99.1 to Form 6-K
Sep 9, 2024, 4:05 PM ET
Abivax presents first-half 2024 financial results
EX-99.1 to Form 6-K
Aug 6, 2024, 6:05 AM ET
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
EX-99.1 to Form 6-K
Jul 16, 2024, 6:00 AM ET
Abivax Provides Operational and Key Program Update
EX-99.1 to Form 6-K
Jun 4, 2024, 4:26 PM ET
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
EX-99.1 to Form 6-K
May 7, 2024, 4:26 PM ET
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
EX-99.1 to Form 6-K
Apr 2, 2024, 10:24 AM ET
Abivax reports 2023 financial results and operational update
EX-99.1 to Form 6-K
Feb 2, 2024, 6:05 AM ET
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
EX-99.1 to Form 6-K
Jan 22, 2024, 6:30 AM ET
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
EX-99.1 to Form 6-K